Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (FDMT), Centene (CNC) and Cencora (COR)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on 4D Molecular Therapeutics (FDMT – Research Report), Centene (CNC – Research Report) and Cencora (COR – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
4D Molecular Therapeutics (FDMT)
Bank of America Securities analyst Daniel Giraldo maintained a Buy rating on 4D Molecular Therapeutics today and set a price target of $31.00. The company’s shares closed last Thursday at $7.61, close to its 52-week low of $3.45.
Giraldo has an average return of
According to TipRanks.com, Giraldo is ranked #3193 out of 12040 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for 4D Molecular Therapeutics with a $33.83 average price target.
See the top stocks recommended by analysts >>
Centene (CNC)
TD Cowen analyst Ryan Langston maintained a Hold rating on Centene today and set a price target of $34.00. The company’s shares closed last Thursday at $47.27.
According to TipRanks.com, Langston has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Centene is a Hold with an average price target of $43.46, representing a -5.6% downside. In a report issued on January 7, Wells Fargo also maintained a Hold rating on the stock with a $43.00 price target.
Cencora (COR)
In a report released today, Allen Lutz from Bank of America Securities maintained a Hold rating on Cencora. The company’s shares closed last Thursday at $355.35.
According to TipRanks.com, Lutz is a 5-star analyst with an average return of
Currently, the analyst consensus on Cencora is a Strong Buy with an average price target of $400.30.
